COVID-19 trials registries data warehouse

https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=064-20

Theresa Jean Ochoa

theresa.ochoa@upch.pe

2020-09-29

Recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

1.- Man or woman over 18 and under 60 years old. 2.- Physicians or nurses who work in areas of care for patients with COVID-19 (emergency, hospitalization, and ICU) in hospitals in Lima, Peru. 3.- Healthy participants, without COVID-19 suggestive symptoms. 4.- Participant who wants to participate and signs the informed consent.

1.- Participant who had a previous diagnosis of COVID-19. 2.- Participant positive in the initial screening for IgM or IgG positive RT-PCR for COVID-19. 3.- Participant with the following comorbidities: hypertension, coronary heart disease, diabetes mellitus, obesity, chronic lung disease, cancer, kidney failure, or other hematological /and immunosuppressive diseases. 4.- Pregnant woman. 5.- Participant that are part of another clinical trial or is receiving any supplement or preventive treatment for COVID 19. 6.- Participant with known allergy to cow´s milk protein.

2

UNIVERSIDAD PERUANA CAYETANO HEREDIA;

18

59

Peru

Health workers

N/A

336

Outcome name:Serology (IgM or IgG) or RT-PCR for COVID-19Measure:Number of COVID-19 infectionsTimepoints:Serology every 4 weeks and RT-PCR if you have symptoms suggestive of COVID-19

Phase 2

[{"arm_notes": "", "treatment_id": 227, "treatment_name": "Bovine lactoferrin", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]